Business Context and Reporting Period
Company: Phio Pharmaceuticals Corp.
Filing Type: Form 8-K (Current Report)
Reporting Date: February 11, 2020 (Event Date); February 13, 2020 (Closing Date)
Context: The Company entered into an Underwriting Agreement with H.C. Wainwright & Co., LLC for a registered public offering of securities to raise capital for its immuno-oncology program and general working capital.
Key Financial Metrics and Transaction Details
| Metric | Value |
|---|---|
| Units Sold | 993,633 |
| Pre-Funded Units Sold | 1,006,367 |
| Total Units Offered | 2,000,000 |
| Offering Price (Units) | $4.00 per Unit |
| Offering Price (Pre-Funded Units) | $3.999 per Pre-Funded Unit |
| Expected Net Proceeds | Approximately $7.0 million |
| Underwriter Warrants Issued | 150,000 shares (7.5% of aggregate) |
| Underwriter Warrant Exercise Price | $5.00 per share |
Revenue, Profit, and Cash Flow: This filing is a Current Report (8-K) regarding a capital raise and does not contain periodic financial statements. Therefore, revenue, profit, operating cash flow, margins, debt, and liquidity metrics are not provided in this document.
Material Changes and Transaction Structure
- Capital Structure Change: The Company issued a mix of Units (Common Stock + Warrants) and Pre-Funded Units (Pre-Funded Warrants + Warrants) to manage beneficial ownership thresholds (4.99%).
- Warrant Terms:
- Public Warrants: Immediately exercisable at $4.00 per share; expire five years from issuance.
- Pre-Funded Warrants: Immediately exercisable at $0.001 per share; exercisable until fully exercised.
- Underwriter Warrants: Immediately exercisable at $5.00 per share; expire February 11, 2025.
- Use of Proceeds: Substantially all net proceeds are designated for the development of the Company's immuno-oncology program, other R&D activities, and general working capital.
Guidance, Outlook, and Risks
Management Commentary: Management intends to utilize the raised capital to advance its immuno-oncology pipeline. The offering closed on February 13, 2020.
Risks and Contingencies:
- Dilution: The issuance of 2,000,000 units plus 150,000 underwriter warrants results in immediate dilution to existing shareholders.
- Market Conditions: The use of Pre-Funded Units suggests the Company sought to maximize proceeds while limiting the immediate dilution impact on specific large investors.
- Regulatory: The offering was conducted pursuant to an effective Form S-1 registration statement (File No. 333-234032).
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received (filing states "expected" $7.0 million).
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific termination provisions and indemnification details.
- Confirm the exact number of shares outstanding post-offering to calculate precise dilution percentages.
- Check subsequent filings for the actual deployment of funds toward the immuno-oncology program.
- Monitor the exercise activity of the Pre-Funded Warrants, as they are immediately exercisable at a nominal price.